Engineering interferons and interleukins for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cytokines are potent immunoregulatory proteins crucial for human physiology and disease.
• They play significant roles in cancer initiation, progression, and elimination.
• Historically, recombinant cytokines have been used to treat cancer, but faced limitations like pleiotropy, poor drug-like properties, and toxicity.

Purpose of the Study:

• To review recent advances in cytokine biology and engineering for cancer immunotherapy.
• To highlight the potential of cytokines in enhancing antitumor immunity.
• To discuss emerging strategies for improving cytokine-based cancer treatments.

Main Methods:

• Review of recent scientific literature on cytokine biology and engineering.
• Analysis of advancements in developing safer and more effective cytokine therapeutics.
• Exploration of how cytokines can be integrated with modern immunotherapies like immune checkpoint inhibitors.

Main Results:

• Cytokines are vital mediators of innate and adaptive antitumor immunity.
• Engineering approaches are being developed to overcome the limitations of traditional cytokine therapy.
• Recent progress shows promise in improving the safety and efficacy of cytokine immunotherapy.

Conclusions:

• Cytokines remain critical for cancer immunotherapy, despite past challenges.
• Novel engineering strategies are enhancing cytokine-based treatments.
• The combination of cytokines with other immunotherapies holds significant potential for cancer treatment.